Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 264 No 7102p944
June 24, 2000 Clinical

Potential for new antimalarial to become drug of choice, researchers say

Tafenoquine, an analogue of primaquine, is effective and well tolerated for prophylaxis against malaria, a Smithkline Beecham sponsored study has found.
Dr Betrand Lell (Institute for Tropical Medicine, University of Tüblingen, Germany) and colleagues explain that the advantage of both primaquine and tafenoquine is that they are active against the liver stages of malaria which means that, unlike antimalarials active against blood stages, they do not need to be continued after exposure ends. However, the short half life and toxicity of primaquine has restricted its use, they say, adding that tafenoquine has an improved safety profile and a longer half life (14 days compared with six hours).
Dr Lell and colleagues conducted a randomised, double-blind study of 426 participants aged 12-20 to assess the safety and efficacy of tafenoquine in Gabon, a malaria-endemic area. After receiving radical cure for malaria (halofantrine) and being assessed as aparasitaemic, the trial participants were randomised to receive tafenoquine or placebo for three days. Tafenoquine was given in one of four doses - 31.25mg, 62.5mg, 125mg and 250mg. Participants were then followed up to day 77.
At day 56, four participants in the placebo group and four in the tafenoquine 31.25mg group had positive smears for the malarial parasite. At higher doses, the first positive smear was found on day 70. At day 77, no participants in the 250mg tafenoquine group had positive smears. The protective efficacy for tafenoquine at day 77 was 0 per cent for 31.25mg, 80 per cent for 62.5mg, 93 per cent for 125mg and 100 per cent for 250mg. The drug was well tolerated, say the researchers. But as it is related to primaquine, it should not be used in individuals with deficiency of glucose-6-phosphate dehydrogenase until its haemolytic potential has been assessed, they add.
Antimalarial regimens requiring daily intake are associated with low compliance among short-term visitors to malarial areas, the authors say. They conclude: "At this stage, a three-day course of 250mg seems a reasonable dose regimen for chemoprophylaxis in a population such as that studied." If the required duration of protection is a few weeks, then tafenoquine has the potential to become the drug of choice, they say (Lancet 2000;355:2041).

Citation: The Pharmaceutical Journal URI: 20001923

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF